Kodiak Sciences Inc. develops retinal medicines as a precommercial biotechnology company focused on diseases that can cause vision loss. News about KOD centers on the ABC Platform and ABCD Platform, the anti-VEGF biologic Zenkuda (tarcocimab tedromer), and bispecific programs including KSI-501 and KSI-101.
Recurring updates cover clinical data in diabetic retinopathy, wet age-related macular degeneration and macular edema secondary to inflammation, along with scientific conference presentations, financial results and capital formation. Company announcements also discuss pipeline expansion into multi-target retinal and ocular disease approaches, including programs directed at inflammation, geographic atrophy and glaucoma optic neuropathy.
Kodiak Sciences (KOD) will present clinical data across three development programs at AAO 2026 in New Orleans, October 9–12, 2026. The meeting will include the first scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration, an eye disease affecting central vision. Charles Wykoff will present these results on October 9.
DAYBREAK topline results, announced September 28, met the primary endpoint for each investigational treatment: both demonstrated vision gains non-inferior to aflibercept at Year 1, meaning neither was worse under the study's comparison criteria. Other presentations cover Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy on October 10 and Phase 1b APEX data for KSI-101 in macular edema secondary to inflammation on October 9.
Kodiak Sciences (KOD) reported that Zenkuda and tabirafusp-ted met their primary vision endpoints in the Phase 3 DAYBREAK wet AMD trial.
At one year, both treatments achieved non-inferior vision gains versus aflibercept. Zenkuda's primary endpoint had a p-value of 0.0007; 54% of its patients reached a six-month dosing interval under strict fluid-based retreatment criteria. Tabirafusp-ted met its vision endpoint (p-value 0.0036) and an anatomical secondary endpoint (p-value <0.0001). Intraocular inflammation rates were 0% for Zenkuda and 0.4% for tabirafusp-ted.
Kodiak plans a fourth-quarter 2026 application for Zenkuda covering wet AMD, diabetic retinopathy and retinal vein occlusion, supported by five positive Phase 3 studies. Its Phase 3 ALTO study of tabirafusp-ted in diabetic macular edema is enrolling patients.
Kodiak Sciences (KOD) will report topline results from its DAYBREAK Phase 3 study on September 28, 2026.
The study evaluates Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) in patients with wet age-related macular degeneration. Kodiak will host a webcast at 8:30 a.m. Eastern Time that day. It will be accessible through the Events and Presentations page on Kodiak’s website, with an archived replay available for a limited time.
Kodiak Sciences (Nasdaq: KOD) reported second quarter 2026 results and progress across its late‑stage retina portfolio. The company is preparing for three major Phase 3 readouts: DAYBREAK topline data for both Zenkuda and KSI-501 in treatment‑naïve wet AMD expected in September 2026, and PEAK Pivotal Analysis 1 topline data for KSI-101 in macular edema secondary to inflammation (MESI) expected in December 2026.
Kodiak completed enrollment of the first 300‑patient PEAK cohort, initiated the ~910‑patient Phase 3 ALTO study of KSI‑501 in diabetic macular edema, and continues BLA preparation activities for Zenkuda. The company ended the quarter with $125.9 million in cash and cash equivalents and expects this to fund operations into 2027. Second quarter 2026 net loss was $65.6 million (vs. $54.3 million in 2025), driven by higher R&D expenses of $56.1 million, while G&A expenses declined to $10.8 million.
Kodiak Sciences (Nasdaq: KOD) reported enrollment of the first patients in its global registrational Phase 3 ALTO trial of investigational bispecific therapy KSI-501 in diabetic macular edema (DME). The study is designed to test superiority of dual IL‑6/VEGF inhibition versus aflibercept (anti‑VEGF) monotherapy.
ALTO will enroll approximately 910 patients, randomized 5:3:5 across two KSI‑501 dosing regimens and an aflibercept control, with treatment and follow‑up over ~96 weeks. The primary endpoint is mean change in best‑corrected visual acuity at Weeks 48–52, with a key secondary endpoint of ≥2‑step DRSS improvement at Week 48. According to Kodiak, ALTO and the fully enrolled DAYBREAK Phase 3 wet AMD trial position KSI‑501, alongside Zenkuda and KSI‑101, within a late‑stage portfolio targeting the $15 billion anti‑VEGF retinal market, with multiple topline data readouts expected between September 2026 and 2Q 2027.
Kodiak Sciences (Nasdaq: KOD) reported completion of enrollment for the first 300-patient pivotal cohort in its global Phase 3 PEAK trial of KSI-101 for macular edema secondary to inflammation (MESI). This cohort underpins Pivotal Analysis 1 of the KSI-101 Phase 3 program.
According to Kodiak, topline clinical data from the 24-week primary endpoint for Pivotal Analysis 1 remain on track for December 2026. The company also plans a second pivotal cohort of approximately 600 subjects across the PEAK and PINNACLE studies, with completion of enrollment expected in 4Q 2026 and topline data anticipated in 2Q 2027. Kodiak positions KSI-101 as a potential therapy for MESI patients at high risk of vision loss, aiming to reduce inflammation, dry the retina and improve vision while avoiding limitations associated with existing systemic and ocular treatments.
Kodiak Sciences (Nasdaq: KOD) announced that CEO Victor Perlroth, M.D., will present at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 11:40 a.m. ET (8:40 a.m. PT).
A live webcast and limited-time replay will be accessible via the company’s investor relations website.
Kodiak Sciences (NASDAQ: KOD) reported Q1 FY2026 results and clinical updates on May 7, 2026. Key clinical highlights: positive Phase 3 GLOW2 topline for Zenkuda in diabetic retinopathy (62.5% ≥2-step DRSS vs 3.3% sham; 85% reduction in sight‑threatening complications), DAYBREAK enrollment ~690 completed, and PEAK/PINNACLE advancing for KSI-101. Financials: $169.5M cash on hand and $58.2M net loss for the quarter; company expects cash to fund operations into 2027.
Kodiak Sciences (Nasdaq: KOD) will present clinical and preclinical advances May 2–7, 2026, at AUS and ARVO, including KSI-101 Week 24 MESI results and an Asian tertiary‑care cohort.
Key disclosed outcomes: 58% of Asian patients achieved ≥15‑letter BCVA gains; mean +17.8 letters at Week 24; CST reduced to <325 µm after one injection; >90% resolved IRF/SRF by Week 8 in APEX.
Kodiak Sciences (Nasdaq: KOD) reported Q4 and full-year 2025 results and program updates on March 31, 2026. Key highlights: positive Phase 3 GLOW2 topline for Zenkuda with 62.5% vs 3.3% ≥2-step DRSS improvement and 85% risk reduction for sight-threatening complications, intent to accelerate a multi-indication BLA, KSI-101 strong Phase 1b APEX data, DAYBREAK enrollment ~690 with topline in Sept 2026, cash $209.9M and $173.0M net proceeds from an 8.0M-share offering supporting operations into 2027.